Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.85 -0.8%	$5.87	$4.65 ▼ $10.24	$97.84M	0.21	71,561 shs	94,740 shs
ORMP Oramed Pharmaceuticals	$2.15 -0.9%	$2.22	$1.82 ▼ $3.09	$87.83M	1.63	142,318 shs	59,111 shs
TENX Tenax Therapeutics	$5.85 -2.0%	$5.82	$2.80 ▼ $7.89	$24.27M	1.61	162,322 shs	8,091 shs
TIL Instil Bio	$22.97 +3.6%	$22.43	$9.62 ▼ $92.00	$150.66M	2.27	185,097 shs	292,777 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	+6.17%	+9.76%	-10.82%	-2.34%
ORMP Oramed Pharmaceuticals	0.00%	+0.94%	-3.59%	-2.71%	-16.34%
TENX Tenax Therapeutics	0.00%	+1.04%	-4.88%	-9.86%	+86.90%
TIL Instil Bio	0.00%	-17.08%	-24.32%	+27.05%	+136.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	2.2155 of 5 stars	3.5	4.0	1.8	0.8	0.0
ORMP Oramed Pharmaceuticals	0.5739 of 5 stars	0.0	3.0	1.9	0.8	0.6
TENX Tenax Therapeutics	1.4012 of 5 stars	3.6	0.0	2.0	0.0	0.6
TIL Instil Bio	3.3466 of 5 stars	3.5	2.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$16.67	184.90% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
TENX Tenax Therapeutics	3.25	Buy	$17.50	199.15% Upside
TIL Instil Bio	3.00	Buy	$119.00	418.07% Upside

Current Analyst Ratings Breakdown

Latest TENX, TIL, COYA, and ORMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/15/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.55M	27.57	N/A	N/A	$2.37 per share	2.47
ORMP Oramed Pharmaceuticals	$1.34M	65.54	N/A	N/A	$3.61 per share	0.60
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$26.99 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.44	N/A	N/A	N/A	N/A	-11.34%	-10.73%	8/13/2025 (Estimated)
TENX Tenax Therapeutics	-$17.60M	-$2.48	N/A	N/A	N/A	N/A	-31.51%	-30.35%	8/12/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)

Latest TENX, TIL, COYA, and ORMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ORMP Oramed Pharmaceuticals	-$0.03	-$0.19	-$0.16	-$0.19	N/A	$2.00 million
5/14/2025	Q1 2025	TENX Tenax Therapeutics	-$0.48	-$0.28	+$0.20	-$0.28	N/A	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	8.84	8.84
ORMP Oramed Pharmaceuticals	N/A	23.94	23.94
TENX Tenax Therapeutics	N/A	40.48	40.48
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
ORMP Oramed Pharmaceuticals	12.73%
TENX Tenax Therapeutics	1.67%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
ORMP Oramed Pharmaceuticals	13.70%
TENX Tenax Therapeutics	3.14%
TIL Instil Bio	47.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
ORMP Oramed Pharmaceuticals	10	40.85 million	35.25 million	Optionable
TENX Tenax Therapeutics	9	4.15 million	4.02 million	Not Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data

TENX, TIL, COYA, and ORMP Headlines

Recent News About These Companies

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

June 2, 2025 | globenewswire.com

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025 | globenewswire.com

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

May 29, 2025 | zacks.com

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

May 29, 2025 | zacks.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...

May 25, 2025 | morningstar.comM

Instil Bio stock price target cut to $105 by H.C. Wainwright

May 24, 2025 | uk.investing.com

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...

May 24, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025 | globenewswire.com

Instil Bio Shares Jump on Trial Updates for Lung Cancer Treatment

May 23, 2025 | marketwatch.com

Instil Bio shares rise on immunotherapy trial updates

May 23, 2025 | msn.com

Instil Bio shares rise after updates on cancer trials

May 23, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 22, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
By Leo Miller | June 3, 2025
View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Breakout Momentum Plays You May Not Know About
By Nathan Reiff | June 6, 2025
View Breakout Momentum Plays You May Not Know About
SoundHound’s AI Growth Story Is Just Getting Started
By Gabriel Osorio-Mazilli | June 16, 2025
View SoundHound’s AI Growth Story Is Just Getting Started

TENX, TIL, COYA, and ORMP Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.85 -0.05 (-0.85%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.03 +0.18 (+3.08%)

As of 06/27/2025 07:41 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.15 -0.02 (-0.92%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.14 -0.01 (-0.42%)

As of 06/27/2025 04:06 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Tenax Therapeutics NASDAQ:TENX

$5.85 -0.12 (-2.01%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$5.84 -0.01 (-0.26%)

As of 06/27/2025 04:04 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Instil Bio NASDAQ:TIL

$22.97 +0.80 (+3.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.88 -0.09 (-0.41%)

As of 06/27/2025 07:23 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time